Bevacizumab (PBS) Reference: HY-P9906A Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
Zenocutuzumab Reference: HY-P99507 Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
Imgatuzumab Reference: HY-P99295 Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer.
Benralizumab Reference: HY-P9923 Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
Manfidokimab Reference: HY-P99724 Manfidokimab (AK120) is an anti-interleukin 4 receptor alpha (IL-4Rα) IgG4 monoclonal antibody.
Tenatumomab Reference: HY-P99566 Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach.
Cepeginterferon alfa-2b Reference: HY-P99497 Cepeginterferon alfa-2b is a pegylated interferon. And Cepeginterferon alfa-2b has PEG with molecular weight of 20 kDa as a pegylated base. Cepeginterferon alfa-2b can be used for research of various diseases, such as hepatitis C virus (HCV), polycythemia vera (PV) and essential thrombocythemia (ET).
Aprutumab Reference: HY-P99007 Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research.
Bleselumab Reference: HY-P99257 Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection.
Suptavumab Reference: HY-P99586 Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
Ziralimumab Reference: HY-P99503 Ziralimumab (ABX-RB2) is an anti-human CD147/BSG monoclonal antibody that can be used for immunosuppression.
Pembrolizumab (anti-PD-1) Reference: HY-P9902A Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.